{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:40:19Z","timestamp":1761514819921,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Medical Research Center Program through the National Research Foundation of Korea","award":["2015R1A5A2009124"],"award-info":[{"award-number":["2015R1A5A2009124"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The use of human intravenous immunoglobulin gamma (IVIG) is associated with thromboembolic events as a complication. There are few reported cases of renal infarction during IVIG use in the general population, but transplant kidney may be more susceptible to thromboembolic events following IVIG use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 41-year-old woman visited with fever and pain at the transplant kidney. Six years ago, she underwent kidney transplantation from a deceased donor. Laboratory and radiologic findings were compatible to septic condition, secondary to acute pyelonephritis. We started antibiotics, inotropics, and IVIG. The patient abruptly developed gross hematuria and urine output decreased to 100\u2009cc\/day during IVIG administration. Renal doppler and pathologic findings revealed renal infarction. Oliguria and azotemia persisted and she is undergoing maintenance hemodialysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our case shows that infarction of transplant kidney can be caused by IVIG use in a patient with severe infection. Thus, when using IVIG for kidney transplant patients with high risk of thromboembolic events, we may be careful to prevent the thromboembolic events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02545-1","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T06:31:33Z","timestamp":1634106693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Renal infarction associated with low dose intravenous immunoglobulin in a kidney transplant recipient with sepsis: a case report and literature review"],"prefix":"10.1186","volume":"22","author":[{"given":"Eun Woo","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Young","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1023-0195","authenticated-orcid":false,"given":"Seok Hui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"issue":"Suppl 1","key":"2545_CR1","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.tmrv.2009.09.010","volume":"24","author":"N Shehata","year":"2010","unstructured":"Shehata N, Palda VA, Meyer RM, Blydt-Hansen TD, Campbell P, Cardella C, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev. 2010;24(Suppl 1):S7\u2013S27.","journal-title":"Transfus Med Rev"},{"key":"2545_CR2","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","volume":"15","author":"SC Jordan","year":"2004","unstructured":"Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol. 2004;15:3256\u201362.","journal-title":"J Am Soc Nephrol"},{"key":"2545_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000056085","volume":"62","author":"Y Sherer","year":"2001","unstructured":"Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology. 2001;62:133\u20137.","journal-title":"Pharmacology"},{"key":"2545_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","volume":"27","author":"ER Stiehm","year":"2013","unstructured":"Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27:171\u20138.","journal-title":"Transfus Med Rev"},{"key":"2545_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"H Orbach","year":"2005","unstructured":"Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29:173\u201384.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2545_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1046\/j.1365-2249.2003.02199.x","volume":"133","author":"VM Brennan","year":"2003","unstructured":"Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133:247\u201351.","journal-title":"Clin Exp Immunol"},{"issue":"Suppl 3","key":"2545_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nep.12248","volume":"19","author":"YH Sin","year":"2014","unstructured":"Sin YH, Kim YJ, Oh JS, Lee JH, Kim SM, Kim JK. Graft rupture after high-dose intravenous immunoglobulin therapy in a renal transplant patient. Nephrology (Carlton). 2014;19(Suppl 3):35\u20136.","journal-title":"Nephrology (Carlton)"},{"key":"2545_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.12701\/yujm.2013.30.2.95","volume":"30","author":"EK Lee","year":"2013","unstructured":"Lee EK, Lee YY, Choi KH. Epidemiology and clinical features of respiratory viruses in pediatric inpatients in a single medical Center in Daegu from 2010 to 2012. Yeungnam Univ J Med. 2013;30:95\u2013100.","journal-title":"Yeungnam Univ J Med"},{"key":"2545_CR9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/cc10597","volume":"16","author":"M Shankar-Hari","year":"2012","unstructured":"Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care. 2012;16:206.","journal-title":"Crit Care"},{"key":"2545_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2169\/internalmedicine.53.1475","volume":"53","author":"SF Tsai","year":"2014","unstructured":"Tsai SF. The first case of atrial fibrillation-related graft kidney infarction following acute pyelonephritis. Intern Med. 2014;53:763\u20136.","journal-title":"Intern Med"},{"key":"2545_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/j.1537-2995.2012.03589.x","volume":"52","author":"GW Daniel","year":"2012","unstructured":"Daniel GW, Menis M, Sridhar G, Scott D, Wallace AE, Ovanesov MV, et al. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion. 2012;52:2113\u201321.","journal-title":"Transfusion"},{"key":"2545_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1365-2710.2011.01287.x","volume":"37","author":"P Bentley","year":"2012","unstructured":"Bentley P, Rosso M, Sadnicka A, Israeli-Korn S, Laffan M, Sharma P. Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure. J Clin Pharm Ther. 2012;37:286\u201390.","journal-title":"J Clin Pharm Ther"},{"key":"2545_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J","volume":"65","author":"AS Wolberg","year":"2000","unstructured":"Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000;65:30\u20134.","journal-title":"Am J Hematol"},{"key":"2545_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2174\/157489008784705359","volume":"3","author":"R Baba","year":"2008","unstructured":"Baba R. Effect of immunoglobulin therapy on blood viscosity and potential concerns of thromboembolism, especially in patients with acute Kawasaki disease. Recent Pat Cardiovasc Drug Discov. 2008;3:141\u20134.","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"2545_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1055\/s-0033-1343894","volume":"39","author":"M Levi","year":"2013","unstructured":"Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39:559\u201366.","journal-title":"Semin Thromb Hemost"},{"key":"2545_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","volume":"16","author":"D Paran","year":"2005","unstructured":"Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16:313\u20138.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2545_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/B978-1-4557-4096-3.00028-3","volume-title":"Kidney transplantation \u2013principles and practice","author":"RDM Allen","year":"2014","unstructured":"Allen RDM. Vascular and lymphatic complications after kidney transplantation. In: Morris PJ, Knechtle SJ, editors. Kidney transplantation \u2013principles and practice. 7th ed. Philadelpia: Elsevier; 2014. p. 435\u201363.","edition":"7"},{"key":"2545_CR18","first-page":"1605","volume-title":"Schrier\u2019s diseases of the kidney","author":"JW O\u2019Bell","year":"2013","unstructured":"O\u2019Bell JW, Bayliss GP, Dworkin LD. Renal artery thrombosis, thromboembolism, atheroemboli, and renal vein thrmobosis. In: Coffman TM, Falk RJ, Molitoris BA, Neilson EG, Schrier RW, editors. Schrier\u2019s diseases of the kidney. 9th ed. Philadelphia: Lippincott Williams and Wilkins; 2013. p. 1605\u201325.","edition":"9"},{"key":"2545_CR19","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1161\/01.CIR.103.13.1718","volume":"103","author":"P Libby","year":"2001","unstructured":"Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103:1718\u201320.","journal-title":"Circulation"},{"key":"2545_CR20","doi-asserted-by":"publisher","first-page":"H619","DOI":"10.1152\/ajpheart.00110.2002","volume":"284","author":"AV Birk","year":"2003","unstructured":"Birk AV, Leno E, Robertson HD, Bolotina VM, Szeto HH. Interaction between ATP and catecholamines in stimulation of platelet aggregation. Am J Physiol Heart Circ Physiol. 2003;284:H619\u201325.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2545_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1440-1797.2010.01399.x","volume":"16","author":"L Huang","year":"2011","unstructured":"Huang L, Kanellis J, Mulley W. Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection. Nephrology. 2011;16:239\u201342.","journal-title":"Nephrology"},{"key":"2545_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16070","volume":"16","author":"MO Soares","year":"2012","unstructured":"Soares MO, Welton NJ, Harrison DA, Peura P, Shankar- Hari M, Harvey SE, et al. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess. 2012;16:1\u2013186.","journal-title":"Health Technol Assess"},{"issue":"9","key":"2545_CR23","first-page":"CD001090","volume":"2013","author":"MM Alejandria","year":"2013","unstructured":"Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013;2013(9):CD001090.","journal-title":"Cochrane Database Syst Rev"},{"key":"2545_CR24","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.clinthera.2019.06.010","volume":"41","author":"Y Yang","year":"2019","unstructured":"Yang Y, Yu X, Zhang F, Xia Y. Evaluation of the effect of intravenous immunoglobulin dosing on mortality in patients with sepsis: a network meta-analysis. Clin Ther. 2019;41:1823\u201338.","journal-title":"Clin Ther"},{"key":"2545_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","volume":"45","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45:486\u2013552.","journal-title":"Crit Care Med"},{"key":"2545_CR26","unstructured":"National Blood Authority. Criteria for clinical use of immunoglobulin in Australia. Assessed 27 Aug 2021. Available from: https:\/\/www.blood.gov.au\/ig-criteria."},{"key":"2545_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2249.2009.04051.x","volume":"159","author":"S Heidt","year":"2010","unstructured":"Heidt S, Roelen DL, Eijsink C, Eikmans M, van Kooten C, Claas FH, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol. 2010;159:199\u2013207.","journal-title":"Clin Exp Immunol"},{"key":"2545_CR28","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1097\/TP.0b013e3181874a36","volume":"86","author":"S Heidt","year":"2008","unstructured":"Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FH, Mulder A. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation. 2008;86:1292\u2013300.","journal-title":"Transplantation"},{"key":"2545_CR29","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/cei.12604","volume":"180","author":"R De Bruyne","year":"2015","unstructured":"De Bruyne R, Bogaert D, De Ruyck N, Lambrecht BN, Van Winckel M, Gevaert P, et al. Calcineurin inhibitors dampen humoral immunity by acting directly on naive B cells. Clin Exp Immunol. 2015;180:542\u201350.","journal-title":"Clin Exp Immunol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02545-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02545-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02545-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T06:40:55Z","timestamp":1634107255000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02545-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2545"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02545-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2021,10,13]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received ethical approval from the institutional review board of Yeungnam University Hospital. Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"338"}}